Updated:
Bio-Path Holdings
Incorporated in 2007 and based in Houston, Texas, Bio-Path Holdings is a clinical-stage biotechnology company founded by Peter Nielsen, who serves as...
Bio-Path Holdings
Incorporated in 2007 and based in Houston, Texas, Bio-Path Holdings is a clinical-stage biotechnology company founded by Peter Nielsen, who serves as President and CEO. The company is built around a proprietary DNAbilize antisense RNAi nanoparticle technology platform, licensed from the University of Texas MD Anderson Cancer Center. The platform's thesis is that it can deliver genetic inhibitors to targeted genes in cancer cells without the toxicities associated with conventional chemotherapy. Nielsen has guided the company from early preclinical work into multiple mid-stage clinical trials, surviving almost two decades on public-market financings without reaching commercialization. Bio-Path runs a narrow pipeline. Its lead candidate, prexigebersen, targets the Grb2 protein in acute myeloid leukemia. A Phase 2 study for that indication missed its primary endpoint in 2020, but the company reported a subset of patients with durable complete remissions and has since refocused on combination therapies with decitabine. The company also advanced prexigebersen into trials for chronic myeloid leukemia and solid tumors, while a second product candidate, BP1002, is being tested in acute myeloid leukemia targeting the Bcl-2 protein. The company has no partners, licensing revenue, or co-development deals as of 2025. As of its most recent public filings, Bio-Path has a micro-cap market capitalization, no product revenue, and an accumulated deficit exceeding $100 million. The company funds operations through periodic at-the-market equity offerings and registered direct offerings. No institutional limited partner structures, private investment funds, or wealth-origin narrative applies — this is a publicly traded biotech that operates like an asset manager in name only, a holding-company shell for intellectual property and regulatory filings. In May 2024, the company executed a 1-for-20 reverse stock split to maintain its Nasdaq listing, a move that reflected its prolonged clinical and financial challenges. Bio-Path's structural differentiator is negative: it functions as a publicly traded clinical-trial vehicle without revenue, without a balance sheet large enough to complete late-stage development, and without a partner to share risk. Its governance is standard for a small-cap biotech, with Nielsen holding both the CEO and President roles since inception. The company's survival depends entirely on the capital markets' willingness to fund management's conviction that antisense oligonucleotide drugs can eventually produce clinical data strong enough to justify an NDA or attract a buyer.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Houston
Corporate office
Houston, TX, United States
Principals
Peter Nielsen
President and Chief Executive Officer
Sector focus
Frequently asked questions
What is Bio-Path Holdings' core drug development platform?
Bio-Path's platform, DNAbilize, is a lipid-substituted antisense RNAi nanoparticle delivery technology. It is designed to deliver single-stranded DNA oligonucleotides that bind to target mRNA and silence oncogenic protein expression. The core claim is that the neutral-charge backbone of the construct reduces toxicity and improves cellular uptake compared to charged oligonucleotides. The technology was in-licensed from MD Anderson Cancer Center.
What happened to prexigebersen's Phase 2 trial in acute myeloid leukemia?
The Phase 2 study of prexigebersen in combination with low-dose cytarabine missed its primary endpoint in 2020. The company subsequently reported a subgroup analysis showing benefit in patients who were treatment-naïve and had certain genetic markers, but the overall trial did not meet statistical significance. Since then, Bio-Path has shifted to pairing prexigebersen with decitabine in a revised clinical strategy in the salvage setting.
How does Bio-Path Holdings fund its operations?
Bio-Path has no product revenue, no licensing income, and no corporate partnerships. It funds all operations, including clinical trials, through periodic equity sales — typically at-the-market offerings or registered direct placements. The accumulated deficit through early 2025 exceeds $100 million. The balance sheet is cash-light, and going-concern risk is a recurring theme in its SEC filings.
Is Bio-Path Holdings structured as a family office or investment firm?
No. Despite the 'Holdings' name, Bio-Path is a publicly traded biotechnology company listed on Nasdaq under the ticker BPTH. It does not manage outside capital, does not operate as a single or multi-family office, and has no investment portfolio. The name reflects its corporate structure as an IP-holding shell for a clinical-stage drug development pipeline, not an asset-management vehicle.
What alternatives to prexigebersen does Bio-Path have in its pipeline?
BP1002, the company's second candidate, is an antisense oligonucleotide targeting Bcl-2, a protein implicated in chemotherapy resistance. It is in Phase 1/1b trials for acute myeloid leukemia. The company has also explored BP1001-A as a liposomal formulation for solid tumors, but progress has been incremental. No IND has been filed for additional indications beyond what is already disclosed in the public pipeline chart.
Who controls investment and strategic decisions at Bio-Path Holdings?
Strategic decisions are governed by a board of directors led by CEO Peter Nielsen, who also holds the president title and has served since the company's 2007 inception. Unlike an allocator-facing firm with an investment committee, Bio-Path's capital-allocation decisions — which drug to test, which trial design to pursue, when to raise equity — are effectively executive management decisions overseen by the board. No investment team, CIO, or external advisor is disclosed as a material decision-maker.
What is the key risk associated with Bio-Path Holdings as a going concern?
The central risk is financial sustainability. With no revenue, an accumulated deficit exceeding $100 million, and a clinical program dependent on equity-market access, Bio-Path requires periodic financings to survive. The 1-for-20 reverse stock split in May 2024 to maintain Nasdaq listing is a visible indicator of the liquidity pressure. If capital markets close or clinical data fails to show a clear path to registration, the company has no fallback assets to monetize.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: